ReviewTherapeutic advances in musculoskeletal disease2015
Atherosclerosis in psoriatic disease: latest evidence and clinical implications.
Review in Therapeutic advances in musculoskeletal disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of metabolic syndrome and its components in psoriatic arthritis compared with general population, cutaneous psoriasis, and other inflammatory arthropathies: a meta-analysis.Clinical rheumatology · 2025Pooled it
- Biologic Therapies and Major Cardiovascular Events in Psoriasis: Updated Systematic Review and Meta-analysis.Dermatology and therapy · 2025Review
- Article
- Association of the Monocyte-to-High Density Lipoprotein Ratio with the FRS and as a Predictor of Cardiovascular Risk in Individuals with Psoriasis Vulgaris.Clinical, cosmetic and investigational dermatology · 2025Article
- Metabolic Syndrome and Its Components in Psoriatic Arthritis.Open access rheumatology : research and reviews · 2022Review
- Trimethylamine N-Oxide, a Gut Microbiota-Derived Metabolite, Is Associated with Cardiovascular Risk in Psoriasis: A Cross-Sectional Pilot Study.Dermatology and therapy · 2021Article
- Review
- Therapeutic wavelengths of ultraviolet B radiation activate apoptotic, circadian rhythm, redox signalling and key canonical pathways in psoriatic epidermis.Redox biology · 2021Article
- Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week.Journal of the American College of Cardiology · 2021Review
- Application of machine learning in understanding atherosclerosis: Emerging insights.APL bioengineering · 2021Review
- Catastrophic stroke burden in a patient with uncontrolled psoriasis and psoriatic arthritis: a case report.BMC neurology · 2020Article
- Changes in metabolic parameters in psoriatic patients treated with secukinumab.Therapeutic advances in chronic disease · 2020Article
- Cardiovascular Risk in Psoriasis Patients: Clinical, Functional and Morphological Parameters.Arquivos brasileiros de cardiologia · 2019Observational
- Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease-Modifying Antirheumatic Drug Treatment.Arthritis care & research · 2019Article
- Inflammasome Signaling and Impaired Vascular Health in Psoriasis.Arteriosclerosis, thrombosis, and vascular biology · 2019Article
- Visceral Adiposity in Psoriasis is Associated With Vascular Inflammation byJACC. Cardiovascular imaging · 2018Observational
- Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows.Frontiers in immunology · 2018Review
- T Cell Hierarchy in the Pathogenesis of Psoriasis and Associated Cardiovascular Comorbidities.Frontiers in immunology · 2018Review
- Favorable Effect of Anti-TNF Therapy on Insulin Sensitivity in Nonobese, Nondiabetic Patients with Inflammatory Bowel Disease.International journal of endocrinology · 2018Article
- Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness.Therapeutic advances in musculoskeletal disease · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is widely accepted that atherosclerosis is caused by chronic low-grade inflammation that results from an interaction between immune mechanisms and metabolic abnormalities within the vessel wall. Population-based studies have found an increased cardiovascular risk in patients with psoriasis and psoriatic arthritis (PsA). This risk is higher in patients with severe disease phenotypes, such as those with severe psoriasis and with musculoskeletal inflammation. Higher levels of inflammatory biomarkers also predict the development of clinical cardiovascular events in these patients. The effect of medications used for PsA on cardiovascular risk is limited to observational studies. Antitumor necrosis factor agents and methotrexate have been associated with reduced cardiovascular risk. These data highlight the importance of screening for cardiovascular risk factors in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.